Sera Prognostics (NASDAQ:SERA) Shares Down 2.3% – Here’s Why

Sera Prognostics, Inc. (NASDAQ:SERA) fell 2.3% on Thursday . The stock traded as low as $2.01 and last traded at $2.14. 42,034 shares were traded during trading, a decline of 48% from the average session volume of 81,165 shares. The stock had previously closed at $2.19.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Sera Prognostics Trading Down 2.3%

The firm has a market cap of $83.80 million, a PE ratio of -3.29 and a beta of 0.92. The stock has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $2.60.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. On average, equities research analysts expect that Sera Prognostics, Inc. will post -0.58 EPS for the current year.

Insider Buying and Selling at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 22,639 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $1.90, for a total transaction of $43,014.10. Following the completion of the transaction, the chief executive officer owned 741,287 shares in the company, valued at $1,408,445.30. This trade represents a 2.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 51,133 shares of company stock worth $99,174 in the last ninety days. Company insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SERA. Captrust Financial Advisors grew its position in shares of Sera Prognostics by 20.0% during the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after purchasing an additional 100,366 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of Sera Prognostics during the first quarter valued at about $193,000. Balentine LLC purchased a new position in shares of Sera Prognostics during the third quarter valued at about $258,000. Jane Street Group LLC purchased a new position in shares of Sera Prognostics during the fourth quarter valued at about $203,000. Finally, Vanguard Group Inc. grew its position in shares of Sera Prognostics by 4.6% during the third quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after purchasing an additional 54,008 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.